Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Julia Driessen, Marie José Kersten*, on behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC), Lydia Visser, Anke van den Berg, Sanne H. Tonino, Josée M. Zijlstra, Pieternella J. Lugtenburg, Franck Morschhauser, Martin Hutchings, Sandy Amorim, Thomas Gastinne, Marcel Nijland, Gerben J.C. Zwezerijnen, Ronald Boellaard, Henrica C.W. de Vet, Anne I.J. Arens, Roelf Valkema, Roberto D.K. Liu, Esther E.E. DreesDaphne de Jong, Wouter J. Plattel, Arjan Diepstra

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP'. Together they form a unique fingerprint.

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology